<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput xmlns:ns2="local" id="11488"><DrugName>E21R</DrugName><DrugSynonyms><Name><Value>E21R</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="24589">Hospira Adelaide Pty Ltd</CompanyOriginator><CompaniesSecondary><Company id="1019372">BV BioCorp</Company><Company id="15262">Vernalis plc</Company><Company id="24589">Hospira Adelaide Pty Ltd</Company></CompaniesSecondary><CrossReferences><SourceEntity id="11488" type="Drug"><TargetEntity id="296125" type="siDrug">E21R</TargetEntity></SourceEntity><SourceEntity id="1019372" type="Company"><TargetEntity id="5035524752" type="organizationId">BV Bio-Corp Pvt Ltd</TargetEntity></SourceEntity><SourceEntity id="15262" type="Company"><TargetEntity id="4295894372" type="organizationId">Vernalis Ltd</TargetEntity></SourceEntity><SourceEntity id="24589" type="Company"><TargetEntity id="4295857650" type="organizationId">Hospira Adelaide Pty Ltd</TargetEntity></SourceEntity><SourceEntity id="1735" type="ciIndication"><TargetEntity id="C93.1" type="ICD10"></TargetEntity><TargetEntity id="10009013" type="MEDDRA"></TargetEntity></SourceEntity><SourceEntity id="291" type="ciIndication"><TargetEntity id="10039073" type="MEDDRA"></TargetEntity><TargetEntity id="D001172" type="MeSH"></TargetEntity><TargetEntity id="-1391695545" type="omicsDisease"></TargetEntity><TargetEntity id="749" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="6833" type="ciIndication"><TargetEntity id="10009018" type="MEDDRA"></TargetEntity><TargetEntity id="D015477" type="MeSH"></TargetEntity><TargetEntity id="98823" type="ORPHANET"></TargetEntity><TargetEntity id="-1293987798" type="omicsDisease"></TargetEntity><TargetEntity id="692" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="725" type="ciIndication"><TargetEntity id="1164" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity></SourceEntity><SourceEntity id="1589" type="Action"><TargetEntity id="1062" type="Mechanism">Apoptosis Inducers</TargetEntity></SourceEntity><SourceEntity id="672" type="Action"><TargetEntity id="3338" type="Mechanism">Anti-GM-CSF</TargetEntity></SourceEntity><SourceEntity id="PTGT-00878" type="ciTarget"><TargetEntity id="56981" type="siTarget">GM-CSF Receptor (GM-CSF-R)</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsSecondary><Indication id="1735">Chronic myelocytic leukemia</Indication><Indication id="291">Rheumatoid arthritis</Indication><Indication id="651">Cancer</Indication><Indication id="6833">Chronic myelomonocytic leukemia</Indication><Indication id="725">Solid tumor</Indication></IndicationsSecondary><ActionsPrimary><Action id="672">GM-CSF receptor antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="2953">Anti-inflammatory</Action><Action id="1545">Anticancer</Action><Action id="1589">Apoptosis stimulator</Action><Action id="1596">Immunomodulator</Action></ActionsSecondary><Technologies><Technology id="1263">Immuno-oncology</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="766">Parenteral formulation unspecified</Technology><Technology id="80">Peptide</Technology></Technologies><LastModificationDate>2017-12-04T15:15:21.000Z</LastModificationDate><ChangeDateLast>2017-12-05T00:00:00.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;As no development has been reported for some time, this program is assumed to be discontinued.&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="1019372" linkType="Company"&gt;BV BioCorp&lt;/ulink&gt;, under license from  &lt;ulink linkID="24589" linkType="Company"&gt;BresaGen&lt;/ulink&gt; (formerly Bresatec Ltd) was developing E21R, a modified form of GM-CSF, for the potential treatment of cancer [&lt;ulink linkID="483433" linkType="reference"&gt;483433&lt;/ulink&gt;]. The drug was formerly being developed by BresaGen and in  March 2003, preclinical findings had shown that E21R exhibited synergy with an established anticancer drug [&lt;ulink linkID="483433" linkType="reference"&gt;483433&lt;/ulink&gt;]. By June 2003, BresaGen had terminated its investigations into E21R and was seeking to outlicense the drug [&lt;ulink linkID="504740" linkType="reference"&gt;504740&lt;/ulink&gt;]; however in February 2006, BresaGen signed an agreement with BV BioCorp for the registration and distribution of GM-CSF in India, Sri Lanka, Bangladesh and Nepal. At that time, it was expected that clinical trials for registration would begin in early 2007 [&lt;ulink linkID="651243" linkType="Reference"&gt;651243&lt;/ulink&gt;],  [&lt;ulink linkID="651192" linkType="Reference"&gt;651192&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;BresaGen had also been developing E21R for the treatment of rheumatoid arthritis (RA), and phase II trials had started by August 2002 [&lt;ulink linkID="466329" linkType="reference"&gt;466329&lt;/ulink&gt;]. However, the RA program was discontinued in March 2003, as marketed compounds hindered patient accrual [&lt;ulink linkID="483433" linkType="reference"&gt;483433&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The drug was previously discovered to act as a GM-CSF antagonist and apoptosis stimulator and was being developed in collaboration with British Biotech as a potential treatment for cancers that express the GM-CSF receptor, including juvenile chronic myeloid leukemia (JCML), chronic myelomonocytic leukemia (CMML), acute myeloid leukemia (AML), solid tumors and juvenile myelomonocytic leukemia (JMML) [&lt;ulink linkID="193679" linkType="reference"&gt;193679&lt;/ulink&gt;], [&lt;ulink linkID="394586" linkType="reference"&gt;394586&lt;/ulink&gt;], [&lt;ulink linkID="368655" linkType="reference"&gt;368655&lt;/ulink&gt;], [&lt;ulink linkID="457266" linkType="reference"&gt;457266&lt;/ulink&gt;]. However, in July 2002, British Biotech and BresaGen terminated their collaborative agreement over E21R and discontinued development of the drug for all indications [&lt;ulink linkID="458914" linkType="reference"&gt;458914&lt;/ulink&gt;]. This decision followed a review of preclinical study data which failed to confirm earlier findings on E21R-induced apoptosis in AML cells. BresaGen was advised not to proceed with a proposed phase I study in children with various myeloid leukemias and placed on hold patient accrual in two clinical studies in adult CMML. At that time, the company intended to review other data with the possibility of repeating certain critical preclinical studies [&lt;ulink linkID="458892" linkType="reference"&gt;458892&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;RHEUMATOID ARTHRITIS&lt;/subtitle&gt;By January 2002, a pilot phase II study into the treatment of rheumatoid arthritis (RA) had been approved [&lt;ulink linkID="436876" linkType="reference"&gt;436876&lt;/ulink&gt;], [&lt;ulink linkID="437327" linkType="reference"&gt;437327&lt;/ulink&gt;]. The Australian trial began in August 2002 in 13 patients who had RA for at least 6 months and were not responding well to standard therapy. The anti-inflammatory activity of the drug was stated at this time to arise from a different mechanism to that which previously led to its investigation for cancer [&lt;ulink linkID="466329" linkType="reference"&gt;466329&lt;/ulink&gt;]. Studies in RA were discontinued in March 2003 [&lt;ulink linkID="483433" linkType="reference"&gt;483433&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;CHRONIC MYELOMONOCYTIC LEUKEMIA&lt;/subtitle&gt;In March 2001, BresaGen and British Biotech commenced patient recruitment for phase II trials to investigate E21R in CMML. The studies were to be conducted over four sites in Australia [&lt;ulink linkID="394586" linkType="reference"&gt;394586&lt;/ulink&gt;], [&lt;ulink linkID="400999" linkType="reference"&gt;400999&lt;/ulink&gt;]. In early July 2002, patient recruitment was ongoing and results were expected in the fourth quarter of 2002 [&lt;ulink linkID="457266" linkType="reference"&gt;457266&lt;/ulink&gt;]. Later in July 2002, accrual into these trials was halted [&lt;ulink linkID="458892" linkType="reference"&gt;458892&lt;/ulink&gt;]. In March 2003, BresaGen confirmed the trial had been discontinued [&lt;ulink linkID="483433" linkType="reference"&gt;483433&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In October 2000, the company reported that E21R had successfully completed phase I trials, proving it was safe in humans, and was to enter phase II trials in Australia to determine the effect of the drug in CMML [&lt;ulink linkID="384671" linkType="reference"&gt;384671&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2002, British Biotech received Orphan Medicinal Products designation for a GM-CSF receptor antagonist for the treatment of JMML from the EMEA [&lt;ulink linkID="475364" linkType="reference"&gt;475364&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;ACUTE MYELOID LEUKEMIA&lt;/subtitle&gt;In July 2001, British Biotech received approval to start a phase II trial investigating the efficacy, safety, tolerability and pharmacokinetics of E21R in patients with AML. In the initial phase of the study, 14 volunteer patients who had either failed to respond to other treatments, or relapsed after an initial response, were to receive a daily dose of E21R for 10 days. Response to treatment was to be determined from bone marrow aspirates and peripheral blood counts. Following review of the safety and response data from the first group of patients, the study was to be expanded to include a total of 35 patients [&lt;ulink linkID="416949" linkType="reference"&gt;416949&lt;/ulink&gt;], [&lt;ulink linkID="417110" linkType="reference"&gt;417110&lt;/ulink&gt;]. The trial started in August 2001 [&lt;ulink linkID="457266" linkType="reference"&gt;457266&lt;/ulink&gt;]. In June 2002, phase II results were expected for the fourth quarter of 2002 [&lt;ulink linkID="430580" linkType="reference"&gt;430580&lt;/ulink&gt;], [&lt;ulink linkID="455271" linkType="reference"&gt;455271&lt;/ulink&gt;]. By July 2002, the trial had been halted as new preclinical data failed to support earlier apoptosis findings. At this time, further preclinical studies were underway to assess the rationale for further development in AML [&lt;ulink linkID="457266" linkType="reference"&gt;457266&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In December 2000, British Biotech reported preclinical results which showed that E21R induces apoptosis in cells from patients with AML [&lt;ulink linkID="394586" linkType="reference"&gt;394586&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;JUVENILE CHRONIC MYELOID LEUKEMIA&lt;/subtitle&gt;In October 2000, the company announced early success in the first ever leukemia patient to be treated with E21R. The patient, who suffered from JCML, was treated on compassionate grounds [&lt;ulink linkID="384671" linkType="reference"&gt;384671&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Early results, reported in 1995, showed that E21R showed in vitro suppression of the hemapoietic progenitor response assessed in a 4-year old boy with JCML. E21R dose-dependently inhibited spontaneous colony formation with an 80% reduction in colony numbers at 10 microg/ml [&lt;ulink linkID="193679" linkType="reference"&gt;193679&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2000, data were published which showed that, in irradiated SCID/NOD mice, E21R reduced the population of implanted human JCML cells compared to controls [&lt;ulink linkID="368655" linkType="reference"&gt;368655&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;JUVENILE MYELOMONOCYTIC LEUKEMIA&lt;/subtitle&gt;In April 2002, E21R was designated an Orphan medicinal product in the EU for JMML [&lt;ulink linkID="445746" linkType="reference"&gt;445746&lt;/ulink&gt;], [&lt;ulink linkID="446483" linkType="reference"&gt;446483&lt;/ulink&gt;]. By July 2002, British Biotech was in discussion with European regulators regarding a clinical program in JMML which was expected to begin in the third quarter of 2002 [&lt;ulink linkID="457266" linkType="reference"&gt;457266&lt;/ulink&gt;]; however, development was discontinued later in July 2002 [&lt;ulink linkID="458914" linkType="reference"&gt;458914&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;SOLID TUMOR&lt;/subtitle&gt;In May 2000, results of an ongoing phase I/Ib trial in patients with solid tumors were presented at the 36th ASCO meeting in New Orleans, LA. The trial was to investigate the safety, toxicity and pharmacokinetics of escalating doses of E21R in cohorts of 3 patients of 10, 30, 100, 300, 600 and 1000 microg/kg/day, sc, for 10 days. Eligible patients had solid tumors (breast, prostate, colon, lung cancer and melanoma) known to express GM-CSF receptors but refractory to treatment. At this time, 10 patients, receiving doses from 10 to 300 microg/kg/day, had an ECOG performance status of 0 in 3, 1 in 5 and 2 in 2. E21R was well tolerated [&lt;ulink linkID="368655" linkType="reference"&gt;368655&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A phase I trial of E21R, initiated in April 1999, involving 18 end-phase cancer patients, mainly with myeloid leukemia or breast cancer, was to be conducted at the Royal Adelaide Hospital. The study was to determine dose tolerance (from 10  to 1000 microg/kg) [&lt;ulink linkID="320957" linkType="reference"&gt;320957&lt;/ulink&gt;]. A 10-day course of treatment in an Australian phase I trial was well tolerated [&lt;ulink linkID="394586" linkType="reference"&gt;394586&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In preclinical testing, no serious toxicity was seen studies in baboons in doses up to 1000 microg/kg/day [&lt;ulink linkID="368655" linkType="reference"&gt;368655&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt; E21R was developed by substituting Glu for Arg at position 21 of GM-CSF. The mutant E21R binds specifically to the GM-CSF receptor alpha chain with comparable affinity to wild-type GM-CSF, but is devoid of high-affinity binding to the GM-CSF alpha beta receptor complex [&lt;ulink linkID="194344" linkType="reference"&gt;194344&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In February 2006, BresaGen signed an agreement with BV BioCorp for the registration and distribution of GM-CSF in India, Sri Lanka, Bangladesh and Nepal [&lt;ulink linkID="651243" linkType="Reference"&gt;651243&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In December 2000, British Biotech and BresaGen entered into a collaborative agreement to develop and commercialize E21R [&lt;ulink linkID="401386" linkType="reference"&gt;401386&lt;/ulink&gt;]. In July 2002, British Biotech and BresaGen terminated their collaborative agreement over E21R and discontinued development of the drug for all indications. At this time, all rights reverted to BresaGen [&lt;ulink linkID="458914" linkType="reference"&gt;458914&lt;/ulink&gt;], [&lt;ulink linkID="458892" linkType="reference"&gt;458892&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2002, BresaGen was granted a second US patent protecting the apoptotic activity of E21R. This patent was also granted in Australia, New Zealand and Singapore and, at that time, an application was proceeding in Europe and Japan. The first patent, granted in the US in 1999, covered the E21R molecule itself [&lt;ulink linkID="436876" linkType="reference"&gt;436876&lt;/ulink&gt;], [&lt;ulink linkID="437327" linkType="reference"&gt;437327&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="24589">Hospira Adelaide Pty Ltd</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-03-26T00:00:00.000Z</StatusDate><Source id="483433" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15262">Vernalis plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1735">Chronic myelocytic leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2002-07-23T00:00:00.000Z</StatusDate><Source id="458914" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1019372">BV BioCorp</Company><Country id="NP">Nepal</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-07-15T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1019372">BV BioCorp</Company><Country id="IN">India</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-07-15T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1019372">BV BioCorp</Company><Country id="BD">Bangladesh</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-07-15T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1019372">BV BioCorp</Company><Country id="LK">Sri Lanka</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-07-15T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24589">Hospira Adelaide Pty Ltd</Company><Country id="AU">Australia</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="6833">Chronic myelomonocytic leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2002-07-23T00:00:00.000Z</StatusDate><Source id="458914" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24589">Hospira Adelaide Pty Ltd</Company><Country id="AU">Australia</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2002-07-23T00:00:00.000Z</StatusDate><Source id="458914" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24589">Hospira Adelaide Pty Ltd</Company><Country id="AU">Australia</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-06-30T00:00:00.000Z</StatusDate><Source id="504740" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="15262">Vernalis plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1735">Chronic myelocytic leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2001-03-07T00:00:00.000Z</StatusDate><Source id="400999" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15262">Vernalis plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1735">Chronic myelocytic leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2000-12-21T00:00:00.000Z</StatusDate><Source id="394586" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24589">Hospira Adelaide Pty Ltd</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-03-26T00:00:00.000Z</StatusDate><Source id="483433" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24589">Hospira Adelaide Pty Ltd</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2002-08-16T00:00:00.000Z</StatusDate><Source id="466329" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24589">Hospira Adelaide Pty Ltd</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2002-01-22T00:00:00.000Z</StatusDate><Source id="436876" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24589">Hospira Adelaide Pty Ltd</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2001-07-12T00:00:00.000Z</StatusDate><Source id="368655" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24589">Hospira Adelaide Pty Ltd</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1735">Chronic myelocytic leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2001-03-08T00:00:00.000Z</StatusDate><Source id="400999" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24589">Hospira Adelaide Pty Ltd</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1735">Chronic myelocytic leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1999-04-01T00:00:00.000Z</StatusDate><Source id="320957" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24589">Hospira Adelaide Pty Ltd</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1735">Chronic myelocytic leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1995-12-18T00:00:00.000Z</StatusDate><Source id="193679" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1019372">BV BioCorp</Company><Country id="IN">India</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-02-20T00:00:00.000Z</StatusDate><Source id="651243" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1019372">BV BioCorp</Company><Country id="LK">Sri Lanka</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-02-20T00:00:00.000Z</StatusDate><Source id="651243" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1019372">BV BioCorp</Company><Country id="BD">Bangladesh</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-02-20T00:00:00.000Z</StatusDate><Source id="651243" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1019372">BV BioCorp</Company><Country id="NP">Nepal</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-02-20T00:00:00.000Z</StatusDate><Source id="651243" type="PR"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1019372">BV BioCorp</OwnerCompany><Country id="EU">EU</Country><Indication id="6833">Chronic myelomonocytic leukemia</Indication><AwardedIndication>Treatment of juvenile myelomonocytic leukaemia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2002-03-18T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1019372">BV BioCorp</OwnerCompany><Country id="EU">EU</Country><Indication id="6833">Chronic myelomonocytic leukemia</Indication><AwardedIndication>Treatment of juvenile myelomonocytic leukaemia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2002-01-23T00:00:00.000Z</MileStoneDate></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-00878"><Name>GM-CSF receptor</Name><SwissprotNumbers></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1019372">BV BioCorp</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="17808">Ligand Pharmaceuticals Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="18767">Pfizer Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>0</CountActive><CountInactive>1</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="5">Drug - Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="108668" title="BV BioCorp to market BresaGen's E21R in India, Sri Lanka, Bangladesh and Nepal"></Deal><Deal id="114231" title="British Biotech to develop BresaGen's E21R"></Deal></Deals><PatentFamilies><PatentFamily id="2049900" number="WO-09504075" title="Haemopoietic growth factor antagonists."></PatentFamily><PatentFamily id="394097" number="WO-09700695" title="Haemopoietic growth factor antagonists and uses therefor."></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Institute Of Medical &amp; Veterinary Science" id="1025439"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Pfizer Inc" id="18767"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput>